OphtiMed Rx

OphtiMed Rx is a pioneering biotechnology research company dedicated to developing innovative solutions in eye therapy. Specializing in preclinical ophthalmic drug development, OphtiMed Rx is committed to addressing critical unmet needs in the treatment of eye diseases. With a focus on cutting-edge research and development, OphtiMed Rx aims to transform the landscape of ophthalmic care.

Located at 4 Barnea, Katzrin, IL, OphtiMed Rx operates with a team of experts in ophthalmology, molecular biology, and biotechnology, driving advancements in the field. OphtiMed Rx is developing a novel molecular therapy for dry Age-related Macular Degeneration (AMD), offering a transformative solution to halt the disease in its early stages and preserve vision.

OphtiMed Rx’s commitment extends to enhancing the quality of life for patients worldwide through vision preservation and independence. Discover how OphtiMed Rx is shaping the future of eye care. We invite the manager of OphtiMed Rx to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.